 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | TBVI |
| Street 1: | Runderweg 6 |
| Street 2: | |
| City: | Lelystad |
| Province: | |
| Post Code: | 8219 PK |
| Country: | Netherlands |
| Phone: | +31 320 277550 |
| Email: | info@tbvi.eu |
| Web Site: | http://www.tbvi.eu |
|
|
||||||||||||||||||||||||||||
General Information | |
| Organization Type - Primary: | Non-Governmental Organization |
| Organization Type - Secondary: | Other Non-Governmental Organization (NGO) |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| TBVI is an independent non-profit foundation that facilitates the development of safe, more effective vaccines to protect future generations against tuberculosis. Since its formation in 2008, TBVI has brought together an integrated network of European universities, institutes and the private sector in the development of new vaccines that are globally accessible and affordable. Research conducted by TBVI’s network has already resulted in new vaccine discoveries, proving that new vaccine approaches can be developed. The organization aims to raise 200 million euros over the next 10 years in its pursuit of eliminating the disease, which currently accounts for 1.8 million deaths annually. |
|
| Total number of staff in your organization: | 6 - 10 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 0 |
| What is your organization's annual budget (USD) dedicated to TB? | $1 MIL-$10 MIL |
| How did you hear about the Stop TB Partnership: | Stop TB communications |
| Why do you wish join the Stop TB Partnership: | Resource mobilization |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
Geographical Reach | |
| Which country is your headquarters located in: | Netherlands |
| Which WHO region is the main focus of your work: | European |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Argentina Belgium Democratic People's Republic of Korea Denmark Finland France Germany Italy Netherlands South Africa Spain Switzerland United Kingdom of Great Britain and Northern Ireland |
Specializations | |
|
Advocacy, communication and social mobilization Funding Research and Development Technical Assistance |
Specializations in Countries | |
| Research and Development | Belgium |
| Research and Development | Democratic People's Republic of Korea |
| Research and Development | Denmark |
| Research and Development | Finland |
| Research and Development | France |
| Research and Development | Germany |
| Research and Development | Italy |
| Research and Development | Netherlands |
| Research and Development | South Africa |
| Research and Development | Spain |
| Research and Development | Switzerland |
| Research and Development | United Kingdom of Great Britain and Northern Ireland |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
New TB Vaccines: We financially support and bring expertise to an integrated network of over 40 universities, institutes and industries to develop more effective, safe vaccines that will be globally accessible and affordable. Research conducted by our mostly European based network has already resulted in promising vaccine discoveries. |
|
Declaration | |
| Declaration of interests: We have no confict of interest with respect to the Global Partnership to Stop TB | |
| Application date: | February 11, 2010 |
| Last updated: | August 26, 2011 |